From bench to bedside: stem and progenitor cell-derived extracellular vesicles in cardiac therapy

Area of Science:

• Cell Biology
• Regenerative Medicine
• Cardiovascular Research

Background:

• Extracellular vesicles (EVs) were once considered cellular waste but are now known to mediate intercellular communication by transferring bioactive molecules.
• EVs from stem and progenitor cells offer cell-free therapeutic potential, mimicking cell transplantation benefits while avoiding associated risks.
• Preclinical studies demonstrate therapeutic effects of various EVs in ischemic heart disease models.

Purpose of the Study:

• To review the evolution of EVs as therapeutic platforms.
• To highlight the potential of EVs in treating acute myocardial infarction.
• To discuss challenges and recent milestones in clinical translation.

Main Methods:

• Literature review of extracellular vesicle research.
• Analysis of preclinical and clinical trial data for cardiac therapies.
• Discussion of manufacturing, standardization, and regulatory aspects.

Main Results:

• EVs show therapeutic promise in preclinical models of ischemic heart disease.
• Phase I trials (EV-AMI and SECRET-HF) are progressing, indicating advancements in clinical translation.
• Despite challenges, recent milestones signify growing momentum in EV-based cardiac therapy.

Conclusions:

• EVs represent a significant evolution from basic discovery to innovative therapeutic platforms.
• Clinical translation of EVs for cardiac conditions, particularly acute myocardial infarction, is advancing.
• Overcoming manufacturing and regulatory hurdles is crucial for widespread clinical adoption of EV therapies.